Eikon Therapeutics

Hayward, United States · Biotechnology, Health Care, Therapeutics · 390 employees

Eikon Therapeutics is advancing breakthrough therapies through the purposeful integration of science and engineering. Our proprietary discovery technologies leverage Nobel Prize-winning super-resolution microscopy, advanced engineering, and high-performance computing to visualize and measure the real-time movement of proteins in living cells, with the goal of bringing important new medicines to pe

Funding history

Funding Round — $350.7M — Feb 2025
Series series d — $350.7M — Feb 2025
Funding Round — $140.8M — Jun 2023
Funding Round — $517.8M — Jan 2022
Series series b — $517.8M — Jan 2022

Recent signals

Feb 06, 2026: SEC 8-K (5.03): Eikon Therapeutics, Inc. has filed an amended and restated certificate of incorporation and amended and restated bylaws, both effective as of February 6, 2026, in connection with the closing of its initial public offering (IPO). The company's board of directors and stockholders approved these changes to be effective immediately prior to the IPO closing. This strategic move positions Eikon Therapeutics for enhanced operational governance after entering the public market, aligning its corporate structure with new business requirements and reporting standards.
Feb 28, 2025: Raised $350.7M
Feb 26, 2025: Raised $350.7M in Series series d
Nov 20, 2024: Eikon Therapeutics Appoints Michael A. Klobuchar as Chief Operating Officer from Merck & Co. Inc.
Jun 01, 2023: Raised $140.8M
Jan 06, 2022: Raised $517.8M
Jan 06, 2022: Raised $517.8M in Series series b
May 13, 2021: Raised $102.5M

See plans & pricing → Track Eikon Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.